Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 July 2025 to Question 67790 on Diabetes: Screening, when he expects the UK National Screening Committee to complete the review of the 2024 submission on autoimmune type 1 diabetes screening through blood testing.

The UK National Screening Committee (UK NSC) is currently awaiting the outcome of the National Institute for Health and Care Excellence’s (NICE) assessment of the drug teplizumab, which is expected in November.

Once the NICE recommendation on teplizumab has been published, the UK NSC will look again at the 2024 annual call submission on autoimmune type 1 diabetes screening through blood testing and will consider whether a fresh review of the evidence for type 1 diabetes screening should be undertaken.